The Antitumor Impact of Combining Hepatic Artery Ligation With Copper Chelators for Liver Cancer.
BACKGROUND: Hepatocellular carcinoma (HCC) is one of the main cancer-related mortality worldwide. Thus, there is a constant search for improvement in treatment strategies to enhance the prognosis of this malignancy. The study aims to investigate the combined antitumor activity of ammonium tetrathiom...
| Publicado en: | Clinical Medicine Insights: Oncology Vol. 17; pp. 1 - 9 |
|---|---|
| Autores principales: | , , , , |
| Formato: | diagnostic images pictorial research tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
Jan-Dec2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=175226940&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 175226940 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: Jan-Dec2023 vid: 17 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 175226940 175226940 175226940 10.1177/11795549231204612 175226940 ppf: 1 ppct: 8 formats: fmt: @attributes: type: P tig: atl: The Antitumor Impact of Combining Hepatic Artery Ligation With Copper Chelators for Liver Cancer. aug: au: Ni Zeng Ye Wang Yuan Wan Hongyu Wang Nan Li affil: Center for Translational Medicine, Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China sug: subj: Hepatic Artery Surgery Liver Neoplasms Surgery Ligation Methods Copper Therapeutic Use Chelating Agents Therapeutic Use Liver Neoplasms Drug Therapy Combined Modality Therapy Chelation Therapy Treatment Outcomes Animal Studies Rats Models, Biological Random Assignment Comparative Studies Copper Blood Neoplasm Invasiveness Anoxia Vascular Endothelial Growth Factors Microvascular Density Immunohistochemistry Liver Neoplasms Prevention and Control Liver Neoplasms Prognosis Embolization, Therapeutic Funding Source ab: BACKGROUND: Hepatocellular carcinoma (HCC) is one of the main cancer-related mortality worldwide. Thus, there is a constant search for improvement in treatment strategies to enhance the prognosis of this malignancy. The study aims to investigate the combined antitumor activity of ammonium tetrathiomolybdate (TM, copper chelator) combined with hepatic artery ligation (HAL) for liver cancer. METHODS: A total of 40 Sprague-Dawley (SD) rats bearing hepatic tumors were randomly divided into four groups: the control group without any treatment (control), HAL only (HAL), given TM by gavage (TM), and given TM combined with HAL (HAL + TM). The concentrations of serum copper were measured at the predetermined time points. Tumor growth rate, overall survival (OS), expression of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), and microvessel density (MVD), as determined by immunohistochemical examination, were compared. RESULTS: HAL treatment transiently could elevate alanine transaminase (ALT) and aspartate transaminase (AST) but resumed to baseline within 1 week. Serum copper was significantly increased in tumor-bearing animals over time. The values of serum copper in the three treatment groups were significantly lower than those in the control group at different time points, with the lowest values observed in the TM group (P < .05). The average tumor size was 30.33 ± 2.58, 20.83 ± 2.93, 16.80 ± 3.84, and 10.88 ± 1.08 mm in the control, HAL, TM, and HAL + TM groups, respectively (HAL + TM vs other groups, all P < .05). In addition, the expression levels of HIF-1α, VEGF, and MVD were significantly lower in the HAL + TM group than those in the other groups (P < .05). The OS of rats in the combined groups was significantly prolonged combined to the other groups (P < .05), with survival time of 19.1 ± 0.64, 25.4 ± 1.24, 25.3 ± 1.78, and 29.9 ± 2.22 days in the control, HAL, TM, and HAL + TM groups, respectively. CONCLUSION: These findings suggest that combined treatment with TM and HAL holds great potential for liver cancer treatment by reducing tumor hypoxia and angiogenesis. The observed results indicate that these combinations may offer a novel target and strategy for interventional therapy of liver cancer. pubtype: Academic Journal doctype: diagnostic images pictorial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|